Detalhe da pesquisa
1.
Expression and purification of active human kinases using Pichia pastoris as a general-purpose host.
Protein Expr Purif
; 179: 105780, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33115654
2.
CD318 is a ligand for CD6.
Proc Natl Acad Sci U S A
; 114(33): E6912-E6921, 2017 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28760953
3.
Effective treatment of HER2-amplified breast cancer by targeting HER3 and ß1 integrin.
Breast Cancer Res Treat
; 155(3): 431-40, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26860947
4.
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
Breast Cancer Res Treat
; 155(3): 521-30, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26875185
5.
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Nature
; 445(7126): 437-41, 2007 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-17206155
6.
HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.
Biochem J
; 447(3): 417-25, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22853430
7.
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy.
Clin Cancer Res
; 29(13): 2351-2361, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36574481
8.
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.
Nat Cancer
; 4(2): 240-256, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36759733
9.
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.
Semin Cell Dev Biol
; 21(9): 944-50, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20816829
10.
Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.
Cancer Res
; 82(16): 2811-2820, 2022 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731927
11.
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.
Cell Rep
; 38(5): 110285, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108526
12.
Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.
Cell Rep
; 38(5): 110291, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108525
13.
A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
Cancer Res Commun
; 2(7): 570-576, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36923283
14.
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.
Sci Rep
; 11(1): 9091, 2021 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33907275
15.
Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A.
Biochem Pharmacol
; 183: 114317, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152346
16.
Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain.
Mol Cancer Res
; 19(6): 957-967, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33727342
17.
The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation.
Am J Pathol
; 174(5): 1756-65, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19349359
18.
Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.
Clin Cancer Res
; 15(7): 2311-22, 2009 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19318475
19.
HER family in cancer progression: From discovery to 2020 and beyond.
Adv Cancer Res
; 147: 109-160, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32593399
20.
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Clin Cancer Res
; 14(23): 7878-83, 2008 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19047117